Specification
| Reactivities | Human |
| Target | CD3xCD19 |
| Approved Therapeutic | Blibio |
| Isotype | His |
| Property | Bispecific Antibody |
| Alernative Name | ; Blincyto; MT103; MEDI-538; MEDI 538; Anti-human CD3 CD19; Human CD3 CD19 bispecific; 853426-35-4 |
| Recommended Isotype | |
| Recommended Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives. |
| Formulation Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >90% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Expression Host | CHO |
| Purification Method | Ni |
| Storage | 2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
| Note | Due to the variability in applications, investigators should consult application references to estimate the appropriate dose or concentration. This dose or concentration can then be further optimized through experimental methods such as dose-response or titration experiments |
Background
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |